RAD51 and cancer: Previous studies have demonstrated that miR-506 directly targets RAD51, thereby sensitizing cancer cells to DNA damage and significantly enhancing the sensitivity of serous ovarian cancer (SOC) cells to cisplatin and PARP inhibitors (111).